Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Reconciliation of revenue from segments to consolidated

The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:


	For the Three Months Ended March 31,
(In millions)	2025		2024
Total revenue	$	2,431.0	$	2,290.5
Less cost and expense:
Cost of sales, excluding amortization and impairment of acquired intangible assets:
Product cost of sales	462.2		377.7
Royalty cost of sales	167.1		164.5
Research and development:
Research and discovery	44.3		47.6
Early stage programs	72.4		84.1
Late stage programs	49.4		32.6
Marketed products	89.5		118.1
Other research and development costs(1)	178.5		163.0
Acquired in-process research and development, upfront and milestone expense	200.7		7.5
Selling, general and administrative	572.5		581.5
Other segment expense(2)	353.9		320.5
Net Income attributable to Biogen Inc.	$	240.5	$	393.4

(1) Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.

(2) Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; other (income) expense, net; and income tax (benefit) expense